Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Nov 30;3(11):15125-15133.
doi: 10.1021/acsomega.8b01754. Epub 2018 Nov 8.

Synthesis and Evaluation of Troponoids as a New Class of Antibiotics

Affiliations

Synthesis and Evaluation of Troponoids as a New Class of Antibiotics

Feng Cao et al. ACS Omega. .

Abstract

Novel antibiotics are urgently needed. The troponoids [tropones, tropolones, and α-hydroxytropolones (α-HT)] can have anti-bacterial activity. We synthesized or purchased 92 troponoids and evaluated their antibacterial activities against Staphylococcus aureus, Escherichia coli, Acinetobacter baumannii, and Pseudomonas aeruginosa. Preliminary hits were assessed for minimum inhibitory concentrations (MIC80) and cytotoxicity (CC50) against human hepatoma cells. Sixteen troponoids inhibited S. aureus/E. coli/A. baumannii growth by ≥80% growth at <30 μM with CC50 values >50 μM. Two selected tropolones (63 and 285) inhibited 18 methicillin-resistant S. aureus (MRSA) strains with similar MIC80 values as against a reference strain. Two selected thiotropolones (284 and 363) inhibited multidrug-resistant (MDR) E. coli with MIC80 ≤30 μM. One α-HT (261) inhibited MDR-A. baumannii with MIC80 ≤30 μM. This study opens new avenues for development of novel troponoid antibiotics to address the critical need to combat MDR bacterial infections.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing financial interest.

Figures

Figure 1
Figure 1
Structures of (A) tropone, (B) tropolone, and (C) α-HT. Structures for all compounds tested are in Figure S1.
Figure 2
Figure 2
Time-killing curves for compounds 63 and 285 against S. aureus (ATCC 29213) and for 284 and 363 against E. coli (ATCC 35218).

References

    1. Smith R.; Coast J. The true cost of antimicrobial resistance. BMJ 2013, 346, f1493.10.1136/bmj.f1493. - DOI - PubMed
    1. Rahal J. J. Antimicrobial Resistance among and Therapeutic Options against Gram-Negative Pathogens. Clin. Infect. Dis. 2009, 49, S4–S10. 10.1086/599810. - DOI - PubMed
    1. Boucher H. W.; Talbot G. H.; Bradley J. S.; Edwards J. E.; Gilbert D.; Rice L. B.; Scheld M.; Spellberg B.; Bartlett J. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 2009, 48, 1–12. 10.1086/595011. - DOI - PubMed
    1. Bentley R. A fresh look at natural tropolonoids. Nat. Prod. Rep. 2008, 25, 118–138. 10.1039/b711474e. - DOI - PubMed
    1. Morita Y.; Matsumura E.; Okabe T.; Fukui T.; Ohe T.; Ishida N.; Inamori Y. Biological Activity of β-Dolabrin, γ-Thujaplicin, and 4-Acetyltropolone, Hinokitiol-Related Compounds. Biol. Pharm. Bull. 2004, 27, 1666–1669. 10.1248/bpb.27.1666. - DOI - PubMed

LinkOut - more resources